Long-term Death Rates, West Nile Virus Epidemic, Israel, 2000

Manfred S. Green,*† Miriam Weinberger,†‡ Judith Ben-Ezer,* Hanna Bin,§ Ella Mendelson,§ Dan Gandacu,¶ Zalman Kaufman,* Rita Dichtiar,* Annette Sobel,# Dani Cohen,*† and Michal Y. Chowers,†**

We studied the 2-year death rate of 246 adults discharged from hospital after experiencing acute West Nile Virus infection in Israel during 2000. The age- and sex-adjusted death rates were significantly higher than in the general population. This excess was greater for men. Significant adverse prognostic factors were age, male sex, diabetes mellitus, and dementia.

West Nile virus (WNV) was first isolated in 1937 (1,2) and has since been found in Europe, Africa, Asia, and North America (1). Human WNV infection was first documented in Israel in 1951 (3). Several outbreaks occurred during the 1950s and during the following 40 years, but mainly sporadic cases occurred (4). In 2000, an epidemic of 428 serologically confirmed cases led to 42 deaths during the acute phase of the illness (5). Little has been reported in the literature on the long-term sequelae of WNV infection. In 1953, 70 patients 18–20 years of age were followed up for ≤11 months, and no serious sequelae or deaths were observed (6). Although 12% of the patients in the New York outbreak in 1999 died during the acute phase of the illness, no deaths occurred among the 35 patients followed up for 1 year after hospitalization (7). The aim of the present study was to determine whether infection with WNV has long-term effects on death rates and to evaluate variables such as age, sex, symptoms and signs, and coexisting conditions as potential prognostic factors.

The Study

Between July 1 and November 30, 2000, 428 patients with serologic diagnoses of WNV infection were reported to the Ministry of Health (MOH) Department of Epidemiology. Diagnosis of WNV infection was made on the basis of symptoms, signs, and laboratory confirmation of the presence of immunoglobulin M (IgM) antibodies. All serologic tests were performed in the MOH’s Central Virology Laboratory by using an IgM-capture enzyme-linked immunosorbent assay in serum or cerebrospinal fluid samples of patients (8). At the time of the epidemic, this was the working definition of a case of WNV infection. While WNV IgM antibodies can persist >1 year (9), a seroepidemiologic study in a healthy population in Israel at the time of the outbreak, using the same laboratory methods, found only 1.2% had IgM antibodies (M.Y. Chowers et al., unpub. data). Thus, few, if any, false-positive results would be expected.

The study population was limited to the 326 hospitalized patients. After excluding 34 patients <20 years of age and the 46 patients who died during hospitalization or within 1 week of discharge, 246 survivors were eligible for follow-up. Demographic data on the cases and date of onset of the disease were obtained from the Department of Epidemiology. The mean ages of the patients were 57.8 years for men and 62.8 years for women. Clinical data on symptoms and coexisting conditions were obtained from the hospital discharge letters. Of eligible survivors, 48.3% had diagnoses of encephalitis or meningoencephalitis, 13.5% had a diagnosis of meningitis, 28.2% had fever, rash, or both, and the other 10% of the survivors had other clinical symptoms.

The patients were monitored to determine whether any deaths occurred from date of hospital discharge until November 30, 2002. Deaths were determined by matching the identity numbers of the case-patients with the data in the national population registry maintained by the Ministry of Interior. We were able to confirm all deaths in the cohort during this period. By November 30, 2002, after an average follow-up period of 24 months (median 26 months, range 1–29 months), 30 of 246 patients had died.

Death certificates were obtained for all case-patients, and all causes of death were recorded and coded by using the International Classification of Disease, Ninth Revision. The coding was reviewed independently by another coder, and the underlying cause of death was determined by using World Health Organization criteria.

Bivariate comparisons between characteristics of the patients who died and the survivors were carried out by using the χ² and t tests. Kaplan-Meier survival curves were constructed for all patients and for men and women separately, and the difference between men and women was compared by using the log-rank test. The age-standardized mortality ratios (SMRs) were computed by using the person-time method with the PAMCOMP program (Institute of Epidemiology and Social Medicine, University of Muenster, Muenster, Germany) (10). SMRs were calculated by dividing the observed number of deaths by the
expected number. Person-months of risk were calculated from the reported onset of the disease until either death or November 30, 2002, whichever occurred first. The expected number of deaths in the study cohort was calculated by multiplying person-months at risk by the national death rates in 1997 (the last year for which detailed published data are available) for the same age and sex categories. Exact 95% confidence intervals (CIs) and p values were calculated by using the Poisson distribution. Attributable risk was computed by the formula (SMR - 1)/SMR. Prognostic factors were evaluated by using Cox proportional hazards regression analysis to estimate adjusted rate ratios while adjusting for other potential determinants of death. The hazard rate ratio (RR) is defined as the ratio of the mortality rate in the group of patients with a given study factor to the rate in those without the factor. We calculated 95% CIs for each adjusted RR. The SAS package version 8.2 (SAS, Cary, NC, USA) was used for all calculations other than the SMRs.

The Kaplan-Meier survival curves are shown for the total cohort and for men and women separately (Figures 1 and 2). Overall, after 1 year, 7.7% had died and after 2 years, 12.2%. After 1 year the death rate was 6.4% for women compared with 9.1% for men (p = 0.025), and after 2 years it was 10.4% for women and 14.1% for men (p = 0.021).

Age-adjusted SMRs, both sex-specific and sex-adjusted, at 6 months, 1 year, and the end of the follow-up, are shown in Table 1. The overall SMR at 1 year was nearly 2.5 times higher than expected (SMR = 2.49, 95% CI 1.50–3.89). Among men, the death rate was >3 times higher than expected, whereas among women the death rate was less than twice as high and not significant. The excess risk at the end of the second year was lower and not significant. Overall, in 50% of the deaths the underlying cause was ascribed to cardiovascular disease. In only 20% was WNV infection given as the underlying cause of death, although this result is clearly influenced by coding practices.

In the Cox regression analyses for evaluating demographic factors and the symptoms and signs as prognostic factors, while simultaneously controlling for each, only age, and especially the oldest age group tested (≥85 years), diabetes mellitus, and dementia were other significant independent predictors of death.

To demonstrate the magnitude of this excess risk, we compared these findings with an Israeli study of deaths within 1 year after hospital discharge among patients with acute myocardial infarction of whom ∼30% had diabetes (S. Bachar, Acute Coronary Syndrome in Israel 2000 study, unpub. data). After age and sex were controlled for, the death rate within 1 year for WNV-infected patients in
the present study was similar to that of patients after myocardial infarction (7.7% vs. 9.5%, p = 0.881). This finding indicates that the 1-year postdischarge death risk in the WNV-infected patients is of a similar magnitude to that of patients with a severe, acute, noninfectious illness.

The main negative prognostic factors in the present study were older age, male sex, diabetes mellitus, and dementia. Similar associations with deaths in the acute phase of the illness have been observed for age (5,11) and diabetes mellitus (5). Thus older age and possibly diabetes mellitus influence both acute-phase and long-term mortality rates. Why long-term mortality rates, not related to preexisting illnesses or age, are higher in men than in women is unknown. In several studies of clinical WNV infection, men appeared to have a higher incidence of disease, but this difference has not been observed in Israel (5).

Survivors of herpes simplex encephalitis have a shorter life expectancy (12,13), and to a lesser extent, so have patients with other viral encephalitides (13). Some of these excess deaths could be attributed to severe neurologic impairment and instability, while other deaths were unrelated to the infection.

The reasons for the increased long-term death rate in survivors of acute WNV infection are not clear. The clinical features described in WNV encephalitis have been described as typical for arboviral encephalitides (1). Severe neurologic sequelae in survivors of invasive WNV infection, and a substantial number of patients do not regain their baseline function (8). This deficit could contribute to an increase in deaths.

In this epidemic in Israel, 2 clades of WNV were isolated (8,14). One was closely related to the 1999 New York isolate and the other to a 1999 Russian isolate and a 1997 Romanian isolate (14). The outbreak was characterized by relatively high case-fatality rates among hospitalized patients; 14% of the patients died during the acute phase (5). This rate is similar to that observed in the New York outbreak (15). No evidence suggests that the virus in Israel was any different in virulence.

The results of this study on the potential long-term impact of WNV infection are relevant for hospitalized patients. They may have been more susceptible to clinical WNV infection. The significant excess death rate indicates that the combined case-fatality rate in all hospitalized patients in the acute and convalescent phases could be >10%, and in patients >65, >30% (5). Thus, such patients require long-term monitoring and support. Possible sex differences in death rates require further investigation.

Acknowledgments

We acknowledge the assistance of the staff of the district health offices and the hospital physicians in the collection of the data.

---

Table 1. Standardized mortality ratios (SMRs) for 246 patients ≥20 years of age discharged from hospital after West Nile virus infection, Israel, 2000, compared with those for the general population during 2 years of follow-up

| Follow-up period | No. | Observed deaths | Expected deaths | SMR | 95% CI |
|------------------|-----|-----------------|-----------------|-----|-------|
| First 12 mo      |     |                 |                 |     |       |
| Men              | 121 | 11              | 3.47            | 3.17† | 1.58–5.67 |
| Women            | 125 | 8               | 4.16            | 1.92† | 0.83–3.79 |
| Total            | 246 | 19              | 7.63            | 2.49‡ | 1.50–3.89 |
| 12–24 mo         |     |                 |                 |     |       |
| Men              | 110 | 6               | 2.91            | 2.06† | 0.75–4.49 |
| Women            | 117 | 5               | 3.74            | 1.34† | 0.43–3.12 |
| Total            | 227 | 11              | 6.64            | 1.66‡ | 0.83–2.96 |

*CI, confidence interval.†Adjusted for age.‡Adjusted for age and sex.

---

Table 2. Cox proportional hazards analysis for the association between coexisting conditions and 2-year death rate follow-up of 246 patients ≥20 years discharged from hospital during a West Nile virus epidemic, Israel, 2000

| Variable                   | B    | RR   | 95% CI          | p    |
|---------------------------|------|------|-----------------|------|
| Age† (y)                  |      |      |                 |      |
| 75–84                     | 2.00 | 7.36 | 2.77–17.71      | <0.0001 |
| ≥85                       | 2.49 | 12.10| 4.24–34.49      | <0.0001 |
| Sex (M = 0, F = 1)        |      | 0.33 | 0.14–0.79       | 0.0124 |
| Diabetes (no = 0, yes = 1) | -1.09| 2.74 | 1.11–6.81       | 0.0234 |
| Ischemic heart disease (no = 0, yes = 1) | 0.17 | 1.19 | 0.52–2.72       | 0.6794 |
| Immunodeficiency (no = 0, yes = 1) | 0.04 | 1.04 | 0.13–8.08       | 0.9696 |
| Cerebrovascular disease (no = 0, yes = 1) | -1.22| 0.29 | 0.07–1.28       | 0.1023 |
| Hypertension (no = 0, yes = 1) | 0.09 | 1.09 | 0.48–2.48       | 0.8365 |
| Dementia (no = 0, yes = 1) | 1.08 | 2.94 | 1.09–7.91       | 0.0330 |

*B, natural logarithm of the hazard rate ratio; RR, hazard rate ratio; CI, confidence interval.†The age group <75 years old was set as a reference.
This study was supported in part by grant No. 14144 from Sandia Laboratories, Albuquerque, New Mexico, USA. The sponsors of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.

Dr Green is director of the Israel Center for Disease Control and professor of epidemiology and preventive medicine at the Sackler Faculty of Medicine, Tel Aviv University. His interests are in the epidemiology of both infectious and chronic diseases and the evaluation of vaccines.

References

1. Campbell GL, Marfin AA, Lanciotti RS, Gubler DJ. West Nile virus. Lancet Infect Dis. 2002;2:519–29.
2. Smithburn KC, Hughes TP, Burke AW, Paul JH. A neurotrophic virus isolated from the blood of a native of Uganda. Am J Trop Med. 1940;20:471–92.
3. Goldblum N, Sterk VM, Paderski B. The clinical features of the disease and the isolation of West Nile virus from the blood of nine human cases. Am J Hyg. 1954;59:89–103.
4. Spigland J, Jasinska-Klingberg W, Hofski E, Goldblum N. Clinical and laboratory observations in the outbreak of West Nile fever in Israel in 1957. Harefuah. 1958;54:275–81.
5. Chowers MY, Lang R, Nassar F, Ben-David D, Giladi M, Robinshtein E, et al. Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg Infect Dis. 2001;7:675–8.
6. Marberg K, Goldblum N, Sterk V, Jasinska-Klingberg W, Klingberg MA. Natural History of West Nile Fever; clinical observations during an epidemic in Israel. Am J Hyg. 1956;64:259–69.
7. Klee AL, Maldin B, Edwin B, Poshni I, Mostashari F, Fine A, et al. Long-term prognosis for clinical West Nile virus infection. Emerg Infect Dis. 2004;10:1405–11.
8. Bin H, Grossman Z, Pokamunski S, Malkinson M, Weiss L, Duvdevani P, et al. West Nile Fever in Israel 1999–2000: from geese to humans. Ann N Y Acad Sci. 2001;951:127–42.
9. Roehrig JT, Nash D, Maldin B, Labowitz A, Martin DA, Lanciotti RS, et al. Persistence of virus-reactive serum immunoglobulin M antibody in confirmed West Nile virus encephalitis cases. Emerg Infect Dis. 2003;9:376–9.
10. Taeger D, Sun Y, Keil U, Straif K. A standalone Windows application for computing exact person-years, standardized mortality ratios and confidence intervals in epidemiological studies. Epidemiology. 2000;11:607–8.
11. Nash D, Mostashari F, Fine A, Miller J, O’Leary D, Murray K, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med. 2001;344:1807–14.
12. McGrath N, Anderson NE, Croxson MC, Powell KF. Herpes simplex encephalitis treated with acyclovir: diagnosis and long term outcome. J Neurol Neurosurg Psychiatry. 1997;63:321–6.
13. Berlit P. The prognosis and long-term course of viral encephalitis. J Neuromununol. 1988;20:117–25.
14. Hindiyeh M, Shulman LM, Mendelson E, Weiss L, Grossman Z, Bin H. Isolation and characterization of West Nile virus from the blood of viremic patients during the 2000 outbreak in Israel. Emerg Infect Dis. 2001;7:748–50.
15. Weiss D, Carr D, Kellachan J, et al. Clinical findings of West Nile virus infection in hospitalized patients, New York and New Jersey, 2000. Emerg Infect Dis. 2001;7:654–8.

Address for correspondence: Manfred S. Green, Israel Center for Disease Control, Gertner Institute, Sheba Medical Center, Tel Hashomer 52621, Israel; fax: 972-3-534-9881; email: m.green@icdc.health.gov.il